Recent events
Recent events tied to this brand in public sources.
Back to profile76 entries · Page 3 of 4
2020
Merck announces U.S. life science production expansions
Merck announced a combined €40 million investment to expand production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire. The expansions are expected to increase capacity and output by the end of 2021 and 2022, respectively, and create nearly 700 manufacturing positions.
2020
Merck and Siemens partner to digitalize production
Merck announced a partnership with Siemens to develop a process control system for modular production of materials and products for the electronics, pharmaceutical and life science industries.
2020
Merck out-licenses atacicept to Vera Therapeutics
Merck, through subsidiary Ares Trading S.A., announced an out-licensing agreement with Vera Therapeutics for further development of investigational therapy atacicept. Vera will assume full responsibility for the program's development and commercialization in all indications.
2020
Iktos and Merck KGaA announce additional AI drug-design collaboration
Iktos announced an additional collaboration with Merck KGaA in AI for drug design. Iktos's generative design technology will be used to support an undisclosed Merck drug-discovery program.
2020
Merck wins Korea Bioprocessing Excellence Award
Merck was recognized with the Korea Bioprocessing Excellence Award at Biologics Manufacturing Korea 2020 for its technology in the upstream cell culture process.
2020
Volansi, Merck and Vidant begin North Carolina drone-delivery project
Volansi began a commercial healthcare drone-delivery project in North Carolina with Merck, piloting delivery of cold-chain medicines from Merck’s Wilson manufacturing site to Vidant Healthplex-Wilson. The project was described as the first of three phases exploring drone technology in the healthcare supply chain.
2020
Merck out-licenses M6495 program to Novartis
Merck announced an out-licensing agreement with Novartis for the M6495 anti-ADAMTS5 Nanobody program. Merck will receive an upfront payment and may receive milestone payments and royalties; Novartis will assume responsibility for development and commercialization.
2020
Merck announces investment to expand HPAPI and ADC capacity in Wisconsin
Merck announced an investment of €59 million to expand high-potency active pharmaceutical ingredient and antibody-drug conjugate capacity at its facility near Madison, Wisconsin. The project was expected to be completed by mid-2022.
2020
Merck and BOE agree to strategic cooperation in OLED
Merck and BOE signed a cooperation agreement for broad collaboration in OLED, including joint evaluation of devices using Merck's OLED materials laboratory, long-term cooperation on OLED material production and supply, and technical exchanges on OLED display applications.
2020
Merck and Shanghai Pudong New Area agree to build Shanghai innovation base
Merck and Shanghai Pudong New Area signed a strategic cooperation agreement to build the Merck Shanghai Innovation Base, an open innovation platform.
2020
Rakuten Medical and Merck enter multi-year cetuximab supply deal
Rakuten Medical announced a multi-year deal under which Merck KGaA will provide cetuximab for Rakuten Medical's ASP-1929 program, including production for clinical trials and commercial sales.
2020
FDA approves a new KEYTRUDA indication
The FDA approved KEYTRUDA monotherapy for certain adult and pediatric patients with unresectable or metastatic TMB-H solid tumors after prior treatment when no satisfactory alternative treatment options are available. The indication was approved under accelerated approval.
2020
FDA approves Recarbrio for bacterial pneumonia
The FDA approved Merck's Recarbrio, a three-drug combination antibiotic injection, for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients aged 18 and older.
2020
RefleXion and Merck announce clinical collaboration
RefleXion Medical announced a clinical collaboration with Merck to evaluate the safety and efficacy of KEYTRUDA in combination with biology-guided radiotherapy in randomized controlled clinical trials for multiple late-stage cancers, including non-small cell lung cancer.
2020
Merck and Baylor extend collaboration on COVID-19 vaccine manufacturing
Merck and Baylor College of Medicine announced an extension of their collaboration to advance manufacturing platforms for Baylor's COVID-19 vaccine candidates. The work will focus on improving production processes and manufacturing readiness for two candidates.
2020
Merck receives U.S. patent allowances for CRISPR-Cas9 technology
Merck announced that two of its CRISPR-Cas9-assisted genome-editing patents had been allowed in the United States.
2020
ICE announces public-private partnership to combat counterfeit PPE
U.S. Immigration and Customs Enforcement announced a partnership with companies including 3M, Amazon, Merck, Pfizer, Citi and Alibaba to help stop counterfeit face masks, coronavirus tests and other PPE and medical supplies from entering the U.S. market.
2020
Merck unveils Bio4C Software Suite
Merck unveiled the Bio4C Software Suite as the next component of its BioContinuum Platform. The suite combines process control, analytics and plant-level automation.
2020
Merck acquires Konica Minolta OLED patent portfolio
Merck KGaA acquired Konica Minolta's OLED patent portfolio for display applications. The acquisition was effective immediately.
2020
Merck and AMCM announce tablet 3D-printing cooperation
Merck and AMCM announced a cooperation agreement on 3D printing tablets, initially targeting GMP-compliant tablet formulation development and production for clinical trials, with commercial manufacturing services envisioned later.